This Day On The Street
Continue to site
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here

Acorda Drug Helps Stroke Patients Walk Better

ARDSLEY, NY ( TheStreet) -- Acorda Therapeutics (ACOR - Get Report) announced mixed results from two proof-of-concept studies Monday aimed at expanding the use of its multiple sclerosis walking drug Ampyra to include patients suffering from strokes and cerebral palsy.

In a study of 83 patients who had experienced a stroke at least six months prior to enrollment, use of twice-daily Ampyra significantly improved walking ability compared to a placebo, Acorda said in a statement. The company didn't provide detailed data on Ampyra's efficacy

Three patients reported seizures during the study. One seizure occurred in a patient treated with a placebo. The two other seizure cases involved patients on Ampyra, although one was deemed an intentional overdose and suicide attempt.

"There were clear efficacy signals in the [Ampya] post-stroke deficits trial and we therefore plan to proceed with a clinical development program for this indication," said Acorda CEO Ron Cohen.

There are approximately 7 million stroke survivors in the U.S., with about half having some difficulty walking, according to the company.

In a separate trial enrolling 24 patients with cerebral palsy, Ampyra "suggested potential treatment activity" related to walking ability and hand strength, Acorda said. The data are still being analyzed to determine if the results are strong enough to justify additional clinical trials.

Ampyra sales in multiple sclerosis totaled $266 million in 2012.

"The post-stroke market is clearly large and would meaningfully expand Ampyra's potential beyond the current MS opportunity," writes ISI Group analyst Mark Schoenebaum, in an email to clients Monday morning. "Ampyra is currently annualizing at about $400M in the U.S. for MS. We calculate that every $50M in additional peak U.S. sales could increase our DCF by around $4-5 (assuming 2027 US patent expiry)."

Acorda shares were up 9% to $34.24 in Monday pre-market trading.

-- Reported by Adam Feuerstein in Boston.

Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Only $9.95
14-Days Free
Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Real Money

More than 30 investing pros with skin in the game give you actionable insight and investment ideas.

Product Features:
  • Access to Jim Cramer's daily blog
  • Intraday commentary and news
  • Real-time trading forums
Only $49.95
14-Days Free
14-Days Free
ACOR $26.11 1.83%
AAPL $92.72 -0.56%
FB $119.49 1.43%
GOOG $711.12 1.38%
TSLA $214.93 1.61%


Chart of I:DJI
DOW 17,740.63 +79.92 0.45%
S&P 500 2,057.14 +6.51 0.32%
NASDAQ 4,736.1550 +19.0610 0.40%

Free Reports

Top Rated Stocks Top Rated Funds Top Rated ETFs